The Effectiveness of Adjuvant PD-1 Inhibitors in Patients With Surgically Resected Stage III/IV Acral Melanoma

Basit Öğe Kaydı
dc.authoridSever, Ozlem Nuray/0000-0003-3462-9360
dc.authoridayhan, murat/0000-0002-0631-4006
dc.authoridKilickap, Saadettin/0000-0003-1637-7390
dc.authoridAgaoglu, Ahmet Burak/0000-0001-5528-7852
dc.authoridOzalp, Faruk Recep/0000-0002-2863-3243
dc.contributor.authorArak, Haci
dc.contributor.authorErkilic, Suna
dc.contributor.authorYaslikaya, Sendag
dc.contributor.authorMocan, Eda Eylemer
dc.contributor.authorAktas, Gokmen
dc.contributor.authorOzdemir, Melek
dc.contributor.authorSemiz, Huseyin Salih
dc.date.accessioned2025-02-22T14:08:53Z
dc.date.available2025-02-22T14:08:53Z
dc.date.issued2024
dc.departmentDicle Üniversitesien_US
dc.description.abstractOur aim was to assess the efficacy of adjuvant programmed cell death protein-1 (PD-1) inhibitors and compare the other adjuvant treatments in patients with surgically resected stage III or IV acral melanoma. This study is a multicenter, retrospective analysis. We included 114 patients with stage III or IV acral malignant melanoma who underwent surgery within the past 10 years. We analyzed the effect of adjuvant programmed cell death protein-1 inhibitors on disease-free survival (DFS). The mean follow-up was 40 months, during which 69 (59.5%) patients experienced recurrence. Among the participants, 64 (56.1%) received systemic adjuvant therapy. Specifically, 48.4% received anti-PD-1 therapy, 29.7% received interferon, 14.1% received tezozolomide, and 7.8% received B-Raf proto-oncogene/mitogen-activated protein kinase inhibitors. Patients who received adjuvant therapy had a median DFS of 24 (10.9-37.2) months, whereas those who did not receive adjuvant therapy had a median DFS of 15 (9.8-20.2) months. Multivariate analysis for DFS revealed that the receipt of adjuvant therapy and lymph node metastasis stage were independent significant parameters (P = 0.021, P = 0.018, respectively). No statistically significant difference was observed for DFS between programmed cell death protein-1 inhibitor treatment and other adjuvant treatments. Regarding overall survival (OS), patients who received adjuvant treatment had a median OS of 71 (30.4-111.7) months, whereas those who did not receive adjuvant treatment had a median OS of 38 (16.7-59.3; P = 0.023) months. In addition, there were no significant differences in OS observed between various adjuvant treatment agents (P = 0.122). In our study, we have shown that adjuvant therapy had a positive effect on both DFS and OS in patients with stages III-IV acral melanoma who underwent curative intent surgery. Notably, we found no significant differences between anti-PD-1 therapy and other adjuvant therapies.en_US
dc.identifier.doi10.1097/CJI.0000000000000508
dc.identifier.endpage189en_US
dc.identifier.issn1524-9557
dc.identifier.issn1537-4513
dc.identifier.issue5en_US
dc.identifier.pmid38333962en_US
dc.identifier.scopus2-s2.0-85192677523en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage182en_US
dc.identifier.urihttps://doi.org/10.1097/CJI.0000000000000508
dc.identifier.urihttps://hdl.handle.net/11468/29698
dc.identifier.volume47en_US
dc.identifier.wosWOS:001277944000005
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherLippincott Williams & Wilkinsen_US
dc.relation.ispartofJournal of Immunotherapyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmzKA_WOS_20250222
dc.subjectacral malignant melanomaen_US
dc.subjectadjuvant therapyen_US
dc.subjectnivolumaben_US
dc.titleThe Effectiveness of Adjuvant PD-1 Inhibitors in Patients With Surgically Resected Stage III/IV Acral Melanomaen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu